ESH AL 2024 | A case study from the ECOG-E1910 trial: early blinatumomab treatment in ALL
Mark Litzow, MD, Mayo Clinic Rochester, Rochester, MN, presents a case study of a 48-year-old woman with acute lymphoblastic leukemia (ALL). She underwent induction chemotherapy followed by blinatumomab in the ECOG-E1910 trial (NCT02003222). Classified as higher-risk due to an IgH translocation, she received haploidentical stem cell transplantation after this regimen, achieving measurable residual disease (MRD) negative complete remission. This case evidences the effective integration of blinatumomab in the early treatment of ALL. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
